An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 7, 2013, Pages 1329-1340

  Rallapalli, P M ^a   Kemball Cook, G ^b   Tuddenham, E G ^b   Gomez, K ^b   Perkins, S J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bioinformatics; Coagulation factor IX; Database; Hemophilia B; Models; Molecular; Mutations; Phenotypes

Indexed keywords

BLOOD CLOTTING FACTOR 9;

ARTICLE; CRYSTAL STRUCTURE; DATA BASE; DNA POLYMORPHISM; GENE DELETION; GENETICS; HEMOPHILIA B; HUMAN; INDEL MUTATION; MISSENSE MUTATION; MUTATION; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; WASTE;

BIOINFORMATICS; COAGULATION FACTOR IX; DATABASE; HEMOPHILIA B; MODELS; MOLECULAR; MUTATIONS; PHENOTYPES;

AMINO ACID SEQUENCE; BLOOD COAGULATION; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; DATABASES, GENETIC; DNA MUTATIONAL ANALYSIS; FACTOR IX; FACTOR IXA; GENETIC PREDISPOSITION TO DISEASE; HEMOPHILIA B; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION; SEVERITY OF ILLNESS INDEX; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880409661     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12276     Document Type: Article

References (45)

1. Anson DS, Choo KH, Rees DJ, Giannelli F, Gould K, Huddleston JA, Brownlee GG. The gene structure of human anti-haemophilic factor IX. EMBO J 1984; 3: 1053-60.
2. Di Scipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest 1978; 61: 1528-38.
3. Bajaj SP, Rapaport SI, Russell WA. Redetermination of the rate limiting step in the activation of factor IX by factor Xla and by factor Vlla/tissue factor. Biochemistry 1983; 22: 4047-53.
4. 2+ on the kinetic parameters of the activation of factor IX by factor XIa. J Biol Chem 1982; 257: 4127-32.
5. Bajaj SP, Sabharwal AK, Gorka J, Birktoft JJ. Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca(2+)-binding site in the protease domain. Proc Natl Acad Sci U S A 1992; 89: 152-6.
6. 2+-binding epidermal growth factor-like domain: its role in protein-protein interactions. Cell 1995; 82: 131-41.
7. Handford PA, Mayhew M, Baron M, Winship PR, Campbell ID, Brownlee GG. Key residues involved in calcium-binding motifs in EGF-like domains. Nature 1991; 351: 164-7.
8. Baron M, Norman DG, Harvey TS, Handford PA, Mayhew M, Tse AG, Brownlee GG, Campbell ID. The three-dimensional structure of the first EGF-like module of human factor IX: comparison with EGF and TGF-alpha. Protein Sci 1992; 1: 81-90.
9. Perkins SJ, Smith KF. Identity of the putative serine-proteinase fold in proteins of the complement system with nine relevant crystal structures. Biochem J 1993; 295: 109-14.
10. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
11. den Uijl IE, Roosendaal G, Fischer K. Insufficient evidence to suggest less stringent therapy in hemophilia B? Blood 2009; 114: 4907-8.
12. Giannelli F, Green PM, Sommer SS, Poon M-C, Kudwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Figueiredo MS, Brownlee GG. Haemophilia B: database of point mutations and short additions and deletions, 7th edition. Nucleic Acids Res 1997; 25: 133-5.
13. Freedman SJ, Furie BC, Furie B, Baleja JD. Structure of the metal-free gamma-carboxyglutamic acid-rich membrane binding region of factor IX by two-dimensional NMR spectroscopy. J Biol Chem 1995; 270: 7980-7.
14. Hopfner KP, Lang A, Karcher A, Sichler K, Kopetzki E, Brandstetter H, Huber R, Bode W, Engh RA. Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. Structure 1999; 7: 989-96.
15. Mathur A, Bajaj SP. Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa. J Biol Chem 1999; 274: 18477-86.
16. Kolkman JA, Lenting PJ, Mertens K. Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor VIII-interactive sites involved in stimulation of enzyme activity. Biochem J 1999; 339: 217-21.
17. Yuan QP, Walke EN, Sheehan JP. The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin. Biochemistry 2005; 44: 3615-25.
18. Bicocchi MP, Pasino M, Rosano C, Molinari AC, Della VE, Lanza T, Bottini F, Acquila M. Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B. Haemophilia 2006; 12: 263-70.
19. Zogg T, Brandstetter H. Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa. Structure 2009; 17: 1669-78.
20. Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci U S A 1995; 92: 9796-800.
21. Saunders RE, O'Connell NM, Lee CA, Perry DJ, Perkins SJ. Factor XI deficiency database: an interactive web database of mutations, phenotypes, and structural analysis tools. Hum Mutat 2005; 26: 192-8.
22. Cooper DN, Ball EV, Krawczak M. The human gene mutation database. Nucleic Acids Res 1998; 26: 285-7.
23. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN. The human gene mutation database: 2008 update. Genome Med 2009; 1: 13.
24. Rybinski H. On first-order-logic databases. ACM Trans Database Syst 1987; 12: 325-49.
25. Claustres M, Horaitis O, Vanevski M, Cotton RG. Time for a unified system of mutation description and reporting: a review of locus-specific mutation databases. Genome Res 2002; 12: 680-8.
26. Fiser A, Sali A. Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol 2003; 374: 461-91.
27. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983; 22: 2577-637.
28. Laffan M, Brown SA, Collins PW, Cumming AM, Hill FG, Keeling D, Peake IR, Pasi KJ. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors Organization. Haemophilia 2004; 10: 199-217.
29. Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease - single center comparison of four different assays. Thromb Haemost 2000; 84: 1127-8.
30. Pouplard C, Trossaert M, LE Querrec A, Delahousse B, Giraudeau B, Gruel Y. Influence of source of phospholipids for APTT-based factor IX assays and potential consequences for the diagnosis of mild haemophilia B. Haemophilia 2009; 15: 365-8.
31. Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000; 15: 7-12.
32. Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985; 24: 3736-50.
33. Rogaev EI, Grigorenko AP, Faskhutdinova G, Kittler EL, Moliaka YK. Genotype analysis identifies the cause of the "royal disease". Science 2009; 326: 817.
34. Pagani F, Raponi M, Baralle FE. Synonymous mutations in CFTR exon 12 affect splicing and are not neutral in evolution. Proc Natl Acad Sci USA 2005; 102: 6368-72.
35. Carlini DB, Stephan W. In vivo introduction of unpreferred synonymous codons into the Drosophila Adh gene results in reduced levels of ADH protein. Genetics 2003; 163: 239-43.
36. Koeberl DD, Bottema CD, Ketterling RP, Bridge PJ, Lillicrap DP, Sommer SS. Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in a human gene. Am J Hum Genet 1990; 47: 202-17.
37. Chen SH, Zhang M, Lovrien EW, Scott CR, Thompson AR. CG dinucleotide transitions in the factor IX gene account for about half of the point mutations in hemophilia B patients: a Seattle series. Hum Genet 1991; 87: 177-82.
38. Matsushita T, Tanimoto M, Yamamoto K, Sugiura I, Hamaguchi M, Takamatsu J, Kamiya T, Saito H. DNA sequence analysis of three inhibitor-positive hemophilia B patients without gross gene deletion: identification of four novel mutations in factor IX gene. J Lab Clin Med 1990; 116: 492-7.
39. Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 1992; 257: 377-9.
40. Saunders RE, Shiltagh N, Gomez K, Mellars G, Cooper C, Perry DJ, Tuddenham EG, Perkins SJ. Structural analysis of eight novel and 112 previously reported missense mutations in the interactive FXI mutation database reveals new insight on FXI deficiency. Thromb Haemost 2009; 102: 287-301.
41. Schmidt AE, Bajaj SP. Structure-function relationships in factor IX and factor IXa. Trends Cardiovasc Med 2003; 13: 39-45.
42. 2+-binding site, proteolysis in the autolysis loop, phospholipid, and factor X. J Biol Chem 1997; 272: 23418-26.
43. Hamaguchi N, Bajaj SP, Smith KJ, Stafford DW. The role of amino-terminal residues of the heavy chain of factor IXa in the binding of its cofactor, factor VIIIa. Blood 1994; 84: 1837-42.
44. Jayandharan G, Shaji RV, Chandy M, Srivastava A. Identification of factor IX gene defects using a multiplex PCR and CSGE strategy-a first report. J Thromb Haemost 2003; 1: 2051-4.
45. Di Michele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138: 305-15.